Quick Listen: Scrip’s Five Must-Know Things
Executive Summary
In this week's podcast edition of Five Must-Know Things: Lilly goes head-to-head in Alzheimer’s; Roche eyes new opportunities for Lucentis; Novartis doubles down on innovation; BMS seeks growth amid generic threats; and the new head of Boehringer Ingelheim India talks to Scrip.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 29 October 2021, including: Eli Lilly and Company goes head-to-head in Alzheimer’s; Roche Holding AG eyes new opportunities for Lucentis; Novartis AG doubles down on innovation; Bristol Myers Squibb Company seeks growth amid generic threats; and the new head of Boehringer Ingelheim GmbH in India talks to Scrip.
This and all our other podcasts are available on the Informa Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Lilly Targets Aduhelm With Aggressive Plans For Donanemab In Alzheimer’s" - Scrip, 26 Oct, 2021.)
(Also see "Cosentyx And Entresto Keep Powering Novartis As Firm Mulls Sandoz Sale" - Scrip, 26 Oct, 2021.)
(Also see "BMS Focuses On Driving Future Growth As Revlimid Generic Launches Near" - Scrip, 27 Oct, 2021.)
(Also see "B-Ingelheim India Chief On Strategy, Jardiance Challenge, Gender Balance In Pharma" - Scrip, 27 Oct, 2021.)